Rituximab Treatment of Patients with Severe, Corticosteroid-Resistant Thyroid-Associated Ophthalmopathy

Ophthalmology

Volumn 117, Issue 1, 2010, Pages

  Khanna, Dinesh ^b   Chong, Kelvin K L ^a,c,e   Afifiyan, Nikoo F ^c   Hwang, Catherine J ^a,c   Lee, Diana K ^a,c   Garneau, Helene Chokron ^a   Goldberg, Robert A ^a   Darwin, Christine H ^b   Smith, Terry J ^b,c   Douglas, Raymond S ^a,b,c,d  

^a JULES STEIN EYE INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; RITUXIMAB;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DECOMPRESSION SURGERY; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSTHYROID OPTIC NEUROPATHY; ENDOCRINE OPHTHALMOPATHY; EXOPHTHALMOS; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN CELL; IRRADIATION; MALE; MEDICAL RECORD REVIEW; ORBIT INFLAMMATION; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; REGULATORY T LYMPHOCYTE; SIDE EFFECT; STRABISMUS; THERAPY EFFECT; TREATMENT RESPONSE; URINARY TRACT INFECTION; VISUAL ACUITY;

EID: 72749085764     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2009.05.029     Document Type: Article

References (38)

1. Jacobson D.L., Gange S.J., Rose N.R., and Graham N.M. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 84 (1997) 223-243
2. McGrogan A., Seaman H.E., Wright J.W., and de Vries C.S. The incidence of autoimmune thyroid disease: a systematic review of the literature. Clin Endocrin (Oxf) 69 (2008) 687-696
3. Weetman A.P. Graves' disease. N Engl J Med 343 (2000) 1236-1248
4. Smith T.J., Tsai C.C., Shih M.J., et al. Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy. Thyroid 18 (2008) 983-988
5. Douglas R.S., Gianoukakis A.G., Goldberg R.A., et al. Circulating mononuclear cells from euthyroid patients with thyroid-associated ophthalmopathy exhibit characteristic phenotypes. Clin Exp Immunol 148 (2007) 64-71
6. Aniszewski J.P., Valyasevi R.W., and Bahn R.S. Relationship between disease duration and predominant orbital T cell subset in Graves' ophthalmopathy. J Clin Endocrinol Metab 85 (2000) 776-780
7. Douglas R.S., Naik V., Hwang C.J., et al. B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. J Immunol 181 (2008) 5768-5774
8. Shlomchik M.J., Craft J.E., and Mamula M.J. From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol 1 (2001) 147-153
9. Bartalena L., Lai A., Compri E., et al. Novel immunomodulating agents for Graves' orbitopathy. Ophthal Plast Reconstr Surg 24 (2008) 251-256
10. Marcocci C., Bartalena L., Tanda M.L., et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 86 (2001) 3562-3567
11. Zoumalan C.I., Cockerham K.P., Turbin R.E., et al. Efficacy of corticosteroids and external beam radiation in the management of moderate to severe thyroid eye disease. J Neuroophthalmol 27 (2007) 205-214
12. Reff M.E., Carner K., Chambers K.S., et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83 (1994) 435-445
13. Nielsen C.H., El Fassi D., Hasselbalch H.C., et al. B-cell depletion with rituximab in the treatment of autoimmune diseases: Graves' ophthalmopathy the latest addition to an expanding family. Expert Opin Biol Ther 7 (2007) 1061-1078
14. Boye J., Elter T., and Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 14 (2003) 520-535
15. Smolen J.S., Keystone E.C., Emery P., et al., Working Group on the Rituximab Consensus Statement. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 66 (2007) 143-150
16. El Fassi D., Nielsen C.H., Hasselbalch H.C., and Hegedus L. The rationale for B lymphocyte depletion in Graves' disease: monoclonal anti-CD20 antibody therapy as a novel treatment option. Eur J Endocrinol 154 (2006) 623-632
17. El Fassi D., Nielsen C.H., Bonnema S.J., et al. B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study. J Clin Endocrinol Metab 92 (2007) 1769-1772
18. Salvi M., Vannucchi G., Campi I., et al. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 156 (2007) 33-40
19. Heemstra K.A., Toes R.E., Sepers J., et al. Rituximab in relapsing Graves' disease, a phase II study. Eur J Endocrinol 159 (2008) 609-615
20. Smith T.J. B cell depletion in Graves' disease: the right answer to the wrong question?. J Clin Endocrinol Metab 92 (2007) 1620-1622
21. Bartley G.B., and Gorman C.A. Diagnostic criteria for Graves' ophthalmopathy. Am J Ophthalmol 119 (1995) 792-795
22. Mourits M.P., Koornneef L., Wiersinga W.M., et al. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br J Ophthalmol 73 (1989) 639-644
23. Ben Simon G.J., Syed H.M., Douglas R., et al. Clinical manifestations and treatment outcome of optic neuropathy in thyroid-related orbitopathy. Ophthalmic Surg Lasers Imaging 37 (2006) 284-290
24. McCann J.D., Goldberg R.A., Anderson R.L., et al. Medial wall decompression for optic neuropathy but lateral wall decompression with fat removal for non vision-threatening indications. Am J Ophthalmol 141 (2006) 916-917
25. Bonara P., Vannucchi G., Campi I., et al. Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for Graves' ophthalmopathy. Clin Rev Allergy Immunol 34 (2008) 118-123
26. Brusko T.M., Putnam A.L., and Bluestone J.A. Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev 223 (2008) 371-390
27. Boissier M.C., Assier E., Biton J., et al. Regulatory T cells (Treg) in rheumatoid arthritis. Joint Bone Spine 76 (2009) 10-14
28. Reis E.A., Athanazio D.A., Lima I., et al. NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis. Rheumatol Int 29 (2009) 469-475
29. Brown K., and Wong W. Diagnostic value of regulatory T cells: a new facet of a much studied cell population. Transplantation 86 (2008) 1485-1491
30. Douglas R.S., Gianoukakis A.G., Kamat S., and Smith T.J. Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves' disease may carry functional consequences for disease pathogenesis. J Immunol 178 (2007) 3281-3287
31. Keystone E., Burmester G.R., Furie R., et al. Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum 59 (2008) 785-793
32. El Fassi D., Banga J.P., Gilbert J.A., et al. Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol 130 (2009) 252-258
33. Ferraro A.J., Drayson M.T., Savage C.O., and MacLennan I.C. Levels of autoantibodies, unlike antibodies to all extrinsic antigen groups, fall following B cell depletion with rituximab. Eur J Immunol 38 (2008) 292-298
34. Kavanaugh A., Rosengren S., Lee S.J., et al. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Ann Rheum Dis 67 (2008) 402-408
35. Salvi M., Vannucchi G., Campi I., et al. Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates. Clin Immunol 131 (2009) 360-365
36. Vignali D.A., Collison L.W., and Workman C.J. How regulatory T cells work. Nat Rev Immunol 8 (2008) 523-532
37. Liossis S.N., and Sfikakis P.P. Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells. Clin Immunol 127 (2008) 280-285
38. Fleischmann R.M. Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab. Semin Arthritis Rheum 38 (2009) 265-280